Design and characterization of a traceable protein kinase Cα

被引:7
作者
Abeyweera, Thushara P.
Rotenberg, Susan A.
机构
[1] CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA
[2] CUNY, Grad Ctr, Flushing, NY 11367 USA
关键词
D O I
10.1021/bi0622017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein kinase C alpha (PKC alpha) is a critical component of pathways that govern cancer-related phenotypes such as invasion and proliferation. Proteins that serve as immediate substrates for PKC alpha offer potential targets for anticancer drug design. To identify specific substrates, a mutant of PKC alpha (M417A) was constructed at the ATP binding site such that it could bind a sterically large ATP analogue derivatized through the N-6 amino group of adenosine ([gamma-P-32]-N-6-phenyl-ATP). Because this analogue could be utilized by the mutant kinase but not by wild-type PKC alpha (or presumably other protein kinase) to phosphorylate peptide or protein substrates, P-32-labeled products were the direct result of the mutant PKC alpha. Kinetic analysis with [gamma-P-32]-N-6-phenyl-ATP revealed that the mutant retained undiminished affinity for the peptide substrate (K-m = 12.4 mu M) and a V-max value (10.3 pmol/min) that was only 3-fold lower than that exhibited by the wild-type enzyme with natural ATP. However, with [gamma-P-32]ATP, the mutant had a somewhat lower affinity (K-m = 82.8 mu M) than the wild-type enzyme (K-m = 9.3 mu M) in vitro but was competent in causing aggressive motility in nonmotile MCF-10A human breast cells (with endogenous ATP), as previously described for wild-type PKC alpha. The FLAG-tagged PKC alpha mutant was expressed in MCF-10A cells and used to co-immunoprecipitate high-affinity substrates from lysates. Immunopellets were reacted with [gamma-P-32]-N-6-phenyl-ATP, and radiolabeled products were analyzed by SDS-PAGE and autoradiography. Mass spectrometry of selected bands identified several known substrates of PKC, thereby validating the methods used in these studies. These findings provide a foundation for future applications of this traceable PKC alpha mutant.
引用
收藏
页码:2364 / 2370
页数:7
相关论文
共 36 条
[1]   Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs [J].
Eblen, ST ;
Kumar, NV ;
Shah, K ;
Henderson, MJ ;
Watts, CKW ;
Shokat, KM ;
Weber, MJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (17) :14926-14935
[2]   IDENTIFICATION OF PHOSPHORYLATION SITES ON MURINE NUCLEAR LAMIN-C BY RP-HPLC AND MICROSEQUENCING [J].
EGGERT, M ;
RADOMSKI, N ;
TRIPIER, D ;
TRAUB, P ;
JOST, E .
FEBS LETTERS, 1991, 292 (1-2) :205-209
[3]   Examination of micro-tip reversed-phase liquid chromatographic extraction of peptide pools for mass spectrometric analysis [J].
Erdjument-Bromage, H ;
Lui, M ;
Lacomis, L ;
Grewal, A ;
Annan, RS ;
McNulty, DE ;
Carr, SA ;
Tempst, P .
JOURNAL OF CHROMATOGRAPHY A, 1998, 826 (02) :167-181
[4]   Identification of new JNK substrate using ATP pocket mutant JNK and a corresponding ATP analogue [J].
Habelhah, H ;
Shah, K ;
Huang, L ;
Burlingame, AL ;
Shokat, KM ;
Ronai, Z .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (21) :18090-18095
[5]   Engineering the serine/threonine protein kinase Raf-1 to utilise an orthogonal analogue of ATP substituted at the N6 position [J].
Hindley, AD ;
Park, S ;
Wang, LL ;
Shah, K ;
Wang, YL ;
Hu, XC ;
Shokat, KM ;
Kolch, W ;
Sedivy, JM ;
Yeung, KC .
FEBS LETTERS, 2004, 556 (1-3) :26-34
[6]   PROTEIN-KINASE-C CONTAINS A PSEUDOSUBSTRATE PROTOTYPE IN ITS REGULATORY DOMAIN [J].
HOUSE, C ;
KEMP, BE .
SCIENCE, 1987, 238 (4834) :1726-1728
[7]   Phorbol ester promotes histone H3-Ser10 phosphorylation at the LDL receptor promoter in a protein kinase C-dependent manner [J].
Huang, W ;
Mishra, V ;
Batra, S ;
Dillon, I ;
Mehta, KD .
JOURNAL OF LIPID RESEARCH, 2004, 45 (08) :1519-1527
[8]  
Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO
[9]  
2-X
[10]   Protein kinase C alpha expression in breast and ovarian cancer [J].
Lahn, M ;
Köhler, G ;
Sundell, K ;
Su, C ;
Li, SY ;
Paterson, BM ;
Bumol, TF .
ONCOLOGY, 2004, 67 (01) :1-10